Lebenthal Global Advisors LLC Purchases New Position in Becton, Dickinson and Company (NYSE:BDX)

Lebenthal Global Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,685 shares of the medical instruments supplier’s stock, valued at approximately $406,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jennison Associates LLC boosted its holdings in Becton, Dickinson and Company by 4.9% in the first quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock worth $99,562,000 after purchasing an additional 18,786 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Becton, Dickinson and Company by 9.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,422 shares of the medical instruments supplier’s stock worth $14,481,000 after purchasing an additional 5,006 shares during the last quarter. Axxcess Wealth Management LLC boosted its holdings in Becton, Dickinson and Company by 30.2% in the first quarter. Axxcess Wealth Management LLC now owns 11,051 shares of the medical instruments supplier’s stock worth $2,735,000 after purchasing an additional 2,565 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Becton, Dickinson and Company by 206.5% in the first quarter. SG Americas Securities LLC now owns 46,328 shares of the medical instruments supplier’s stock worth $11,464,000 after purchasing an additional 31,215 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. boosted its holdings in Becton, Dickinson and Company by 24.0% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 32,175 shares of the medical instruments supplier’s stock worth $7,962,000 after purchasing an additional 6,220 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on BDX shares. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James dropped their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Evercore ISI lifted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Stifel Nicolaus lifted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Price Performance

Shares of BDX stock traded up $2.02 on Friday, hitting $235.61. 112,890 shares of the stock traded hands, compared to its average volume of 1,366,284. The firm has a market cap of $68.10 billion, a price-to-earnings ratio of 48.04, a PEG ratio of 1.77 and a beta of 0.42. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $259.92. The firm has a 50 day simple moving average of $237.58 and a two-hundred day simple moving average of $235.04. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating the consensus estimate of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company’s revenue was up 2.3% on a year-over-year basis. During the same period last year, the firm earned $2.96 EPS. As a group, equities research analysts predict that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.